In medical research, a scenario often entertained is randomized controlled 2 2 factorial design with a binary outcome. By utilizing the concept of potential outcomes, Dasgupta et al. proposed a randomization-based causal inference framework, allowing flexible and simultaneous estimations and inferences of the factorial effects. However, a fundamental challenge that Dasgupta et al.'s proposed methodology faces is that the sampling variance of the randomization-based factorial effect estimator is unidentifiable, rendering the corresponding classic ''Neymanian'' variance estimator suffering from over-estimation. To address this issue, for randomized controlled 2 2 factorial designs with binary outcomes, we derive the sharp lower bound of the sampling variance of the factorial effect estimator, which leads to a new variance estimator that sharpens the finite-population Neymanian causal inference. We demonstrate the advantages of the new variance estimator through a series of simulation studies, and apply our newly proposed methodology to two real-life datasets from randomized clinical trials, where we gain new insights.
Introduction
Since originally introduced to conduct and analyze agricultural experiments, 1,2 factorial designs have been widely applied in social, behavioral and biomedical sciences, because of their capabilities to evaluate multiple treatment factors simultaneously. In particular, over the past half-century, randomized controlled 2 2 factorial designs have become more well adopted in medical research, in which the research interest often lies in assessing the (main and interactive) causal effects of two distinct binary treatment factors on a binary outcome. Among the lengthy list of medical studies that are powered by 2 2 factorial designs, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] one of the most impactful examples is the landmark Physicians' Health Study, 13 in which over 10,000 patients were randomly assign to four experimental arms: (1) placebo aspirin and placebo À carotene; (2) placebo aspirin and active À carotene; (3) active aspirin and placebo À carotene; and (4) active aspirin and active À carotene. This study contained multiple important end-points that were binary, e.g. cardiovascular mortality.
For traditional treatment-control studies (i.e. 2 1 factorial designs), a well-developed and popular methodology to conduct causal inference is the potential outcomes framework, 14, 15 where we define causal effects as comparisons (difference, ratio, etc.) between the treated and control potential outcomes, which are assumed to be fixed for each experimental unit. Consequently, estimation and inference of causal effects solely depend on treatment assignment randomization, which is often regarded as the gold standard for causal inference. 16 As a randomization-based methodology, the potential outcomes framework possesses several advantages against other existing approaches, many of which are model-based. For example, it is fully non-parametric and therefore more robust to model mis-specification, and better suited for finite population analyses, which under certain circumstances are more appropriate as pointed by several researchers. 17 Realizing the salient feature of the potential outcomes framework, Dasgupta et al. 18 formally extended it to 2 K factorial designs, by defining the factorial effects as linear contrasts of potential outcomes under different treatment combinations, and proposing the corresponding estimation and inferential procedures. Dasgupta et al. 18 argued that by utilizing the concept of potential outcomes, the proposed randomization-based framework ''results in better understanding of'' factorial effects, and ''allows greater flexibility in statistical inference.'' However it is worth mentioning that, while ''inherited'' many desired properties of the potential outcomes framework, inevitably it also inherited a fundamental issue -the sampling variance of the randomization-based estimator for the factorial effects is unidentifiable, and therefore the corresponding classic ''Neymanian'' variance estimator suffers from the issue of overestimation in general (see Section 6.5 of Imbens and Rubin 19 for a detailed discussion) -in fact, as pointed by Aronow et al., 20 it is generally impossible to unbiasedly estimate the sampling variance, because we simply cannot directly infer the association between the potential outcomes. For treatment-control studies, this problem has been extensively investigated and somewhat well-resolved, for binary 21, 22 and more general outcomes. 20 However, to the best of our knowledge, similar discussions appear to be absent in the existing literature for 2 K factorial designs, which are of both theoretical and practical interests. Motivated by several real-life examples in medical research, in this paper we take a first step towards filling this important gap, by sharpening randomized-based causal inference for 2 2 factorial designs with binary outcomes. To be more specific, we derive the sharp (formally defined later) lower bound of the sampling variance of the factorial effect estimator, and propose the corresponding ''improved'' Neymanian variance estimator.
The paper proceeds as follows. In Section 2 we briefly review the randomization-based causal inference framework for 2 2 factorial designs, focusing on binary outcomes. Section 3 presents the bias (i.e. magnitude of over-estimation) of the classic Neymanian variance estimator, derives the sharp lower bound of the bias, proposes the corresponding improved Neymanian variance estimator, and illustrates our results through several numerical and visual examples. Section 4 conducts a series of simulation studies to highlight the performance of the improved variance estimator. In section 5 we have applied our newly proposed methodology to two real-life medical studies, where new insights are gained. Section 6 discusses future directions and concludes. We relegate the technical details to Appendices 1 and 2.
2 Randomization-based causal inference for 22 factorial designs with binary outcomes 2.1 2 2 Factorial designs To review Neymanian causal inference for 2 2 factorial designs, we adapt materials by Dasgupta et al. 18 and Lu, 23 and tailor them to the specific case with binary outcomes. In 2 2 factorial designs, there are two treatment factors (each with two-levels coded as À1 and 1) and four distinct treatment combinations z j ð j ¼ 1, . . . , 4Þ: To define them, we rely on the model matrix 24
The treatment combinations are z 1 ¼ ðÀ1, À1Þ, z 2 ¼ ðÀ1, 1Þ, z 3 ¼ ð1, À1Þ and z 4 ¼ ð1, 1Þ, and later we will use h 1 , h 2 and h 3 to define the factorial effects.
Randomization-based inference
By utilizing potential outcomes, Dasgupta et al. 18 proposed a framework for randomization-based causal inference for 2 K factorial designs. For our purpose, we consider a 2 2 factorial design with N ! 8 experimental units. Under the Stable Unit Treatment Value Assumption, 25 for i ¼ 1, . . . , N, we define Y i ðz j Þ as the potential outcome of unit i under treatment combination z j , and let
In this paper we only consider binary outcomes, i.e. Y i ðz j Þ 2 f0, 1g for all i ¼ 1, . . . , N and j ¼ 1, . . . , 4:
To save space, we introduce two sets of notations. First, we let
Consequently, instead of specifying the potential outcomes ðY 1 , . . . , Y N Þ entry by entry, we can equivalently characterize them using the ''joint distribution'' vector ðD 0000 , D 0001 , . . . , D 1110 , D 1111 Þ, where the indices are ordered binary representations of 0 to 15. Second, for all non-empty sets f j 1 , . . . , j s g & f1, . . . , 4g, we let
Therefore, for j ¼ 1, . . . , 4, the average potential outcome for z j is
Define the lth (individual and population) factorial effects as
for l ¼ 1, 2, 3, which correspond to the main effects of the first and second treatment factors, and their interaction effect, respectively. Having defined the treatment combinations, potential outcomes and factorial effects, next we discuss the treatment assignment and observed data. Suppose for j ¼ 1, . . . , 4, we randomly assign n j (a pre-specified constant) units to treatment combination z j : Let
be the treatment assignments, and
be the observed outcome for unit i, and
Therefore, the average observed potential outcome for z j isp j ¼ n obs j =n j , for all j ¼ 1, . . . , 4: Denotê p ¼ ðp 1 ,p 2 ,p 3 ,p 4 Þ 0 , and the randomization-based estimators for
which are unbiased with respect to the randomization distribution. Motivated by several relevant discussions in the existing literature, 18,26-28 Lu 23, 29 proved the consistency and asymptotic Normality of the randomization-based estimator in equation (2) , and derived its sampling variance as
where for j ¼ 1, . . . , 4
is the variance of potential outcomes for z j , and
is the variance of the lth (individual) factorial effects in equation (1) .
3 Improving the Neymanian variance estimator 3.1 Background
Given the sampling variance in equation (3), we estimate it by substituting S 2 j with its unbiased estimate
and substituting S 2 ð l Þ with its lower bound 0 (due to the fact that it is not identifiable, because none of the individual factorial effects il 's are observable). Consequently, we obtain the ''classic Neymanian'' variance estimator is
This estimator overestimates the true sampling variance on average by
unless strict additivity 18 holds, i.e.
which is unlikely to happen in real-life scenarios, especially for binary outcomes. 30, 31 We summarize and illustrate the above results by the following example.
Example 1. Consider a hypothetical 2 2 factorial design with N ¼ 16 units, whose potential outcomes, factorial effects and summary statistics are shown in Table 1 , from which we draw several conclusions -first, the population-level factorial effects in equation (1) are À0.1563, À0.0313. and À0.0313, respectively; second, the sampling variances of the randomization-based estimators in equation (2) are 0.0425, 0.0493, and 0.0493, respectively; third, if we employ the classic Neymanian variance estimator in equation (4), on average we will overestimate the sampling variances by 52.5%, 31.6%, and 31.6%, respectively.
Sharp lower bound of the sampling variance
As demonstrated in the previous sections, the key to improve the classic Neymanian variance estimator (4) is obtaining a non-zero and identifiable lower bound of S 2 ð l Þ: To achieve this goal, we adopt the partial identification philosophy, commonly used in the existing literature to bound either the randomization-based sampling variances of causal parameters, 20 or the causal parameters themselves. [32] [33] [34] We first present two lemmas, which play central roles in the proof of our main theorem.
and the equality in equation (6) holds if and only if X j2J lþ
We provide the proofs of Lemmas 1 and 2 in Appendix 1. With the help of the lemmas, we present an identifiable sharp lower bound of S 2 ð l Þ:
The equality in equation (9) holds if and only if equation (7) or (8) holds. 
By employing the inclusion-exclusion principle and Bonferroni's inequality, we provide the proof of Theorem 1 in Appendix 1. The lower bound in Theorem 1 is sharp in the sense that it is compatible with the marginal counts of the potential outcomes ðN 1 , N 2 , N 3 , N 4 Þ (and consequently l ). To be more specific, for fixed values of ðN 1 , N 2 , N 3 , N 4 Þ, there exists a hypothetical set of potential outcomes
Theorem 1 effectively generalizes the discussions regarding binary outcomes by Robins 21 and Ding and Dasgupta, 22 from treatment-control studies to 2 2 factorial designs. In particular, the conditions in equations (7) and (8) echo the parallel results by Ding and Dasgupta, 22 and therefore we name them the ''generalized'' monotonicity conditions on the potential outcomes. However, intuitive and straightforward as it seems, proving Theorem 1 turns out to be a non-trivial task.
The ''improved'' Neymanian variance estimator
The sharp lower bound in equation (9) leads to the ''improved'' Neymanian variance estimator
which is guaranteed to be smaller than the classic Neymanian variance estimator in equation (4) for any observed data, because the correction term on the right hand side of equation (10) is always non-negative. For example, for balanced designs (i.e. n 1 ¼ n 2 ¼ n 3 ¼ n 4 ) with large sample sizes, the relative estimated variance reduction is
We illustrate the above results by the following numerical example.
Example 2. Consider a balanced 2 2 factorial design with N ¼ 400 experimental units, so that ðn 1 , n 2 , n 3 , n 4 Þ ¼ ð100, 100, 100, 100Þ: For the purpose of visualizing the estimated variance reduction under various settings, we repeatedly draw
for 5000 times, and plot the corresponding 1 's in Figure 1 . We can draw several conclusions from the results. First, for 13% of the times 1 is smaller than 1%, corresponding to cases where l % À0:5, 0 or 0.5. Second, for 13% of the times, 1 is larger than 10%. Third, the largest 1 is approximately 20.5%, corresponding to the case where ðn obs 1 , n obs 2 , n obs 3 , n obs 4 Þ ¼ ð0, 0, 16, 14Þ and 1 ¼ 0:15: As pointed out by several researchers, 20,21 the probabilistic consistency of the factorial effect estimator l guarantees that the improved Neymanian variance estimator still overestimates the sampling variance on average, unless one of the generalized monotonicity conditions in equations (7) and (8) holds. Nevertheless, it does improve the classic Neymanian variance estimator in equation (4) , and more importantly, this improvement is the ''best we can do'' without additional information. In the next section, we conduct simulation studies to demonstrate the finite-sample properties of, and to compare the performances of, the classic and improved Neymanian variance estimators.
Simulation studies
To save space, we focus on the first factorial effect 1 and its randomization-based statistical inference. To mimic the empirical examples that we will reanalyze in the next section, we choose the sample size N ¼ 800: Moreover, to (at least to some extent) explore the complex dependence structure of the potential outcomes, we adopt the latent multivariate Normal model for the underlying data generation mechanism. To be more specific, let
and assume that for each i
We consider the following six cases l ¼ ðÀ2, À2, À2, À2Þ zfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}|fflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{ We choose the above values for l, so that the corresponding factorial effects 1 % 0 (the approximaition is due to finite-sample fluctuation) for Cases 1 and 2. Similarly, 1 % 0:25 for Cases 3 and 4, and 1 % 0:5 for Cases 5 and 6. Therefore, we can examine the scenarios where the sharp lower bound S 2 LB ð l Þ in equation (10) is either small or large in magnitude. Moreover, we partially adopt the simulation settings by Dasgupta et al. 18 and let
which corresponds to negatively correlated, independent and positively correlated potential outcomes, respectively. The aforementioned data generation mechanism resulted in 18 ''joint distributions'' of the potential outcomes ðD 0000 , D 0001 , . . . , D 1111 Þ, which we report in the third column of Table 2 . For each simulation case (i.e. row of Table 2 ), we adopt the following three-step procedure:
(1) Use equations (1) and (3) to calculate 1 , the sampling variance of its randomization-based estimator and its lower bound, respectively, and report them in the fourth to sixth columns of Table 2 ; (4) and (10), the last six columns contain their percentages of overestimation of the true sampling variance, and the average lengths and coverage rates of their corresponding confidence intervals.
(2) Independently draw 10,000 treatment assignments from a balanced 2 2 factorial design with ðn 1 , n 2 , n 3 , n 4 Þ ¼ ð200, 200, 200, 200Þ; (3) For each observed data-set, use equations (2), (4) and (10) to calculate the point estimate of 1 , the classic and improved Neymanian variance estimates, respectively, based on which we construct two 95% confidence intervals.
To examine the performances of the classic and improved Neymanian variance estimators in equations (4) and (10) , in the last six columns of Table 2 , we report the relative (i.e. percentage wise) overestimations of the true sampling variance, the average lengths and the coverage rates of their corresponding confidence intervals of the two estimators, respectively.
We can draw several conclusions from the results. First, because of the non-negative correction termŜ 2 LB ð l Þ=N, for all cases the improved Neymanian variance estimator (10) reduces the overestimation of the sampling variance, shortens the confidence intervals and achieves better coverage rates without under-covering. For example, in Case 4 with ¼ 1=2, the improved Neymanian variance estimator reduces the coverage rate from 0.974 to 0.956, achieving near nominal level. Second, by comparing Case 1 with Case 2 (or 3 with 4, and 5 with 6), we can see that for a fixed l , although the absolute magnitude of the correction term is the same, the performance (i.e. reduction of percentage of overestimation, average length and coverage rate) of the improved Neymanian variance estimator might differ significantly, depending on the ''marginal distributions'' of the potential outcomes (characterized by the mean parameter l). Third, for a fixed marginal distribution, the performance of the improved Neymanian variance estimator might also differ significantly, depending on the dependence structure of the potential outcomes (characterized by the association parameter ). Fourth, in certain scenarios, while the improved Neymanian variance estimator only slightly shortens the confidence interval, it leads to a nonignorable improvement on coverage rates. For example, in Case 5 with ¼ 0, a less than 5% shorter confidence interval reduces the coverage rate from 0.976 to 0.966.
To take into account alternative data generation mechanisms and thus provide a more comprehensive pircute, in Appendix 2 we conduct an additional series of simulation studies, where we focus on several discrete outcome distributions. The results largely agree with the above conclusions.
Empirical examples 5.1 A study on smoking habits
In 2004, the University of Kansas Medical Center conducted a randomized controlled 2 2 factorial design to study the smoking habits of African American light smokers, i.e. those ''who smoke 10 or fewer cigarettes per day for at least six months prior to the study''. 35 The study focused on two treatment factors -nicotine gum consumption (2 gm/day vs. placebo), and counseling (health education vs. motivational interviewing). Among N ¼ 755 participants, n 1 ¼ 189 were randomly assigned to z 1 (placebo and motivational interviewing), n 2 ¼ 188 to z 2 (placebo and health education), n 3 ¼ 189 to z 3 (nicotine gum and motivational interviewing), and n 4 ¼ 189 to z 4 (nicotine gum and health education). The primary outcome of interest was abstinence from smoking 26 weeks after enrollment, determined by whether salivary cotinine level was less than 20 ng/ml. Ahluwalia et al. 35 reported that ðn obs 1 , n obs 2 , n obs 3 , n obs 4 Þ ¼ ð13, 29, 19, 34Þ: We reanalyze this data set in order to illustrate our proposed methodology. To save space we only focus on 2 , the main effect of counseling. The observed data suggests that its point estimate 2 ¼ À0:082, the 95% confidence intervals based on the classic and improved Neymanian variance estimators are (À0.129, À0.035) and (À0.127, À0.037), respectively. While the results largely corroborate Ahluwalia et al.'s 35 analysis and conclusion, the improved variance estimator does provide a narrower confidence interval -the variance estimate by the improved Neymanian variance estimator is 92.1% of that by the classic Neymanian variance estimator.
A study on saphenous-vein coronary-artery bypass grafts
The Post Coronary Artery Bypass Graft trial is a randomized controlled 2 2 factorial design conducted between March 1989 and August 1991, on patients who were ''21 to 74 years of age, had low-density lipoprotein (LDL) cholesterol levels of no more than 200 mg/deciliter, and had had at least two saphenous-vein coronary bypass grafts placed 1 to 11 years before the start of the study''. 36 The study concerned two treatment factors -LDL cholesterol level lowering (aggressive, goal is 60-85 mg/deciliter vs. moderate), and low-dose anticoagulation (1 mg warfarin vs. placebo). Among N ¼ 1351 participants, n 1 ¼ 337 were randomly assigned to z 1 (moderate LDL lowering and placebo), n 2 ¼ 337 to z 2 (moderate LDL lowering and warfarin), n 3 ¼ 339 to z 3 (aggressive LDL lowering and placebo), and n 4 ¼ 337 to z 4 (aggressive LDL lowering and warfarin). For the purpose of illustration, we define the outcome of interest as the composite end point (defined as death from cardiovascular or unknown causes, nonfatal myocardial infarction, stroke, percutaneous transluminal coronary angioplasty, or coronaryartery bypass grafting) four years after enrollment. Campeau et al. 36 (in Table 5 and Figure 2 , pp. 160) reported that n obs 1 þ n obs 2 ¼ 103, n obs 3 þ n obs 4 ¼ 85, n obs 2 þ n obs 4 ¼ 89, n obs 4 ¼ 68, which implies that ðn obs 1 , n obs 2 , n obs 3 , n obs 4 Þ ¼ ð82, 21, 17, 68Þ: We reanalyze the interactive effect 3 : The observed data suggests that 3 ¼ 0:166, and the 95% confidence intervals based on the classic and improved Neymanian variance estimators are (0.130, 0.202) and (0.133, 0.200), respectively. Again, the improved Neymanian variance estimator provides a narrower confidence interval, because its variance estimate is only 87.7% of that by the classic Neymanian variance estimator. Moreover, the results suggest a statistically significant interactive effect between LDL cholesterol lowering and low-dose anticoagulation treatments, which appeared to be absent in Campeau et al.'s original paper. 36 
Concluding remarks
Motivated by several empirical examples in medical research, in this paper we studied Dasgupta et al.'s 18 randomization-based causal inference framework, under which factorial effects are defined as linear contrasts of potential outcomes under different treatment combinations, and the corresponding difference-in-means estimator's only source of randomness is the treatment assignment itself. However, as pointed out by Aronow et al., 20 a long standing challenge faced by such finite-population frameworks is estimating the true sampling variance of the randomization-based estimator. In this paper, we solve this problem and therefore sharpen randomizationbased causal inference for 2 2 factorial designs with binary outcomes, which is not only of theoretical interest, but also arguably the most common and important setting for medical research among all factorial designs. To be more specific, we propose a new variance estimator improving the classic Neymanian variance estimator by Dasgupta et al. 18 The key idea behind our proposed methodology is obtaining the sharp lower bound of the variance of unit-level factorial effects, and using a plug-in estimator for the lower bound. Through several numerical, simulated and empirical examples, we demonstrated the advantages of our new variance estimator.
There are multiple future directions based on our current work. First, although more of theoretical interests, it is possible to extend our methodology to general 2 K factorial designs, or even more complex designs such as 3 k or fractional factorial designs. Second, we can generalize our existing results for binary outcomes to other scenarios (continuous, time to event, et al.). Third, although this paper focuses on the ''Neymanian'' type analyses, the Bayesian counterpart of causal inference for 2 2 factorial designs might be desirable. However, it is worth mentioning that, instead of adopting model-based approaches, 37 we seek to extend Rubin's 38 and Ding and Dasgupta's 22 finite-population Bayesian causal inference framework to factorial designs, which requires a full Bayesian model on the joint distribution of the potential outcomes under all treatment combinations. However, this direction faces several challenges. For example, characterizing the dependence structure in multivariate binary distributions can be extremely complex, as pointed out by Cox 39 and Dai et al. 40 Fourth, it would be interesting to explore the potential use of our proposed variance estimator for constructions of non-parametric tests in factorial designs. 41, 42 Fifth, it is possible to further improve our variance estimator, by incorporating pre-treatment covariate information. All of the above are our ongoing or future research projects.
Proof of Lemma 2. We only prove the case where l ¼ 1 and h l ¼ ðÀ1, À1, 1, 1Þ 0 , because other cases (l ¼ 2, 3) are analogous. We break down equation (6) to two parts
and
and prove them one by one. It is worth emphasizing that, for the equality in equation (6) to hold, we only need the equality in either equation (11) or (12) to hold. To prove equation (11) , note that
and therefore equation (11) is equivalent to
We use the inclusion-exclusion principal to prove the above. First, it is obvious that
and the equality holds if and only if the set fi :
Second, note that
The equality in equation (15) holds if and only if fi :
Third, by the same argument we have N 23 þ N 24 À N 234 N 2 ð17Þ and the equality in equation (17) holds if and only if fi :
Fourth, by applying the similar logic, we have N 134 þ N 234 À N 1234 N 34 ð19Þ and the equality in equation (19) holds if and only if fi :
By combining equations (13) , (15) , (17) and (19), we have proved that equation (11) holds. Moreover, the equality in equation (11) holds if and only if equations (13) , (15) , (17) and (19) hold simultaneously, i.e. the four conditions in equations (14) , (16) , (18) and (20) are met simultaneously. We leave it to the readers to verify that this is indeed equivalent to equation (7), i.e. for all j ¼ 1, . . . , N
The proof of equation (12) is symmetrical, because it is equivalent to
In particular, the equality in equation (12) holds if and only if equation (8) holds (again we leave the verification to the readers). The proof is complete.
Proof of Theorem 1. The proof directly follows from (1), and Lemma 1 and 2.* 
